Supreme Court ruling ‘incremental positive’ for Gilead, says Jefferies

Jefferies notes that the Supreme Court just ruled in favor of the U.S. government in the Kennedy v. Braidwood case, which means HIV PrEP mandated coverage stand and the USPSTF and current recommendations remain in place. The firm, which calls this “an incremental positive” for Gilead (GILD) that removes an overhang going into the launch for Yeztugo, has a Buy rating and $130 price target on Gilead shares.